AU2024203045A1 — New combination of active agents for the treatment of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)

USPTO Abstract

P0018880AUD1 ABSTRACT The application refers to a novel combination treatment/ combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I R A N N C N o HN OH I, wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitior of formula III CI N N N * N o HN OH III or apharmaceutically acceptable salt thereof.